Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer

NCT01809210 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV

Interventions

DRUG: selumetinib
DRUG: gemcitabine
DRUG: cisplatin
DRUG: carboplatin
DRUG: pemetrexed

Sponsor

AstraZeneca